Abstract
HypertrofickĂĄ obstrukÄnĂ kardiomyopatie je charakterizovĂĄna ztluĹĄtÄnĂm stÄn a zvÄtĹĄenĂm masy myokardu nedilatovanĂŠ levĂŠ komory srdeÄnĂ bez vysvÄtlujĂcĂch hemodynamickĂ˝ch pĹĂÄin a pĹĂtomnosti obstrukce ve vĂ˝tokovĂŠm traktu levĂŠ komory. V minulosti byla invazivnĂ nefarmakologickou metodou volby k redukci septĂĄlnĂ hypertrofie chirurgickĂĄ myektomie, kterou v devadesĂĄtĂ˝ch letech vystĹĂdala alkoholovĂĄ septĂĄlnĂ ablace, nynĂ vĹĄeobecnÄ uĹžĂvanĂĄ, bezpeÄnĂĄ a ĂşÄinnĂĄ metoda v redukci septĂĄlnĂ hypertrofie. Toto review se zabĂ˝vĂĄ novou metodu pouĹžĂvanou v redukci septĂĄlnĂ hypertrofie, kterou je endokardiĂĄlnĂ radiofrekvenÄnĂ ablace septĂĄlnĂ hypertrofie (ERASH). NaĹĄe prĂĄce shrnuje dosud publikovanĂŠ studie a srovnĂĄvĂĄ jejich vĂ˝sledky s jinĂ˝mi metodami redukce septĂĄlnĂ hypertrofie. ERASH se jevĂ jako srovnatelnÄ ĂşÄinnĂĄ a bezpeÄnĂĄ metoda jako alkoholovĂĄ septĂĄlnĂ ablace se srovnatelnĂ˝m poklesem gradientu ve vĂ˝tokovĂŠm traktu levĂŠ komory a subjektivnĂm zlepĹĄenĂm stavu pacienta charakterizovanĂ˝m poklesem v tĹĂdÄ NYHA. © 2022, ÄKS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
